LGND

MKT CAP:$6B

Ligand Pharmaceuticals Incorporated

Market Cap

$6B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$296.26+$106.15 (+55.84%)

Jul 15, 2026

52W High $320.4252W Low $129.63

Company Details

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; ...

Leadership

Todd C. Davis Ph.D.

CEO & Director

Octavio Espinoza

Chief Financial Officer

Andrew T. Reardon J.D.

Chief Legal Officer & Secretary

Paul J. Hadden

Senior Vice President of Investments & Business Development

Melanie J. Herman CPA

Executive Director of Investor Relations and Financial Planning & Analysis

Keith Marschke Ph.D.

Senior Vice President of Biology & Scientific Affairs

Vincent D. Antle Ph.D.

Senior Vice President of Technical Operations & QA - Capitsol

Karen R. Reeves M.D.

Senior VP of Investments & Head of Clinical Strategy

Richard B. Baxter

Senior VP of Investment Operations

Scott M. Plesha

CEO of Pelthos Therapeutics

IPO Date

Nov 18, 1992

Website

www.ligand.com

Key Metrics TTM

Revenue

$274M

+74.6% YoY

Net Income

$154M

EPS (Diluted)

Free Cash Flow

$123M

Revenue / Share

$13.80

Gross Margin

98.6%

Operating Margin

36.7%

Net Margin

55.9%

FCF Margin

44.8%

P/S

23.1x

P/E

41.3x

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Revenue by Product

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee